论文部分内容阅读
目的探讨超声造影参数预测乳腺癌新辅助化疗疗效的应用价值。方法 56例乳腺癌患者分别于新辅助化疗前及第2次化疗结束后进行超声造影检查。记录超声造影参数及4~6个周期新辅助化疗后的病理学疗效,比较新辅助化疗前、后超声造影参数的差异及不同病理学疗效分组间超声造影参数的差异。结果 56例乳腺癌病灶经新辅助化疗2个周期后的超声造影峰值强度(17.82±3.29 db)低于化疗前(23.80±3.74 db),差异有统计学意义(t=19.948,P<0.001)。化疗前、后两次乳腺癌病灶超声造影峰值强度变化率与病理反应分级呈正相关(spearman r=0.839,P<0.001)。4~6个周期新辅助化疗后的病理有效组与无效组的峰值强度变化率分别为0.28±0.07和0.16±0.04(t=5.27,P=0.026)。结论超声造影参数中峰值强度变化率有助于预测乳腺癌新辅助化疗的疗效。
Objective To explore the value of contrast-enhanced ultrasound (CEUS) parameters in predicting the efficacy of neoadjuvant chemotherapy for breast cancer. Methods 56 patients with breast cancer were examined by ultrasound before neoadjuvant chemotherapy and after the end of second chemotherapy. The parameters of contrast-enhanced ultrasound and pathological outcomes after neoadjuvant chemotherapy for 4 to 6 cycles were recorded. The difference in contrast parameters before and after neoadjuvant chemotherapy and the difference in parameters of contrast-enhanced ultrasonography between different pathological groups were compared. Results The peak intensity of contrast-enhanced ultrasound (17.82±3.29 db) after neoadjuvant chemotherapy for 56 breast cancer lesions was lower than that before chemotherapy (23.80±3.74 db). The difference was statistically significant (t=19.948, P<0.001). . There was a positive correlation between the peak intensity of contrast-enhanced ultrasound and the grade of pathological reaction before and after chemotherapy (spearman r=0.839, P<0.001). The peak intensity change rates of the effective and non-effective groups after neoadjuvant chemotherapy for 4 to 6 cycles were 0.28±0.07 and 0.16±0.04, respectively (t=5.27, P=0.026). Conclusions The rate of change of peak intensity in CEUS parameters is helpful to predict the efficacy of neoadjuvant chemotherapy for breast cancer.